Latest Headlines

Latest Headlines

Perrigo sees growth, but its sales are trimmed by a hit to contract manufacturing

Over-the-counter drug specialist Perrigo has been on an expansion roll the last two years, culminating with its $8.6 billion buyout last summer of Ireland-based drug company Elan. Its latest earnings reflect that growth, with sales up 11% and adjusted net income jumping 45%.

Perrigo pulls 18 batches of acetaminophen for infants on dosing fears

The FDA has asked drugmakers to recall several products with dosing systems or potency variations that could lead to dangerous overdoses.

Pharma M&A gets soft in second quarter

According to a new report from consultant PwC, there was a decline in the two Vs--volume and value--after some big deals in the first quarter pushed both of those up.

Which are pharma's top 4 innovators? Hint: It's not the big guys

There's been a lot of talk about a dearth of innovation in the pharma business. But some drugmakers don't lack creativity. In fact, a few of them actually made Forbes' latest list of 100 most innovative companies on the globe.

OTC specialist Perrigo nabs Elan and its tax rate for $8.6B

Perrigo has snatched up Elan for $8.6 billion in a cash-and-stock deal. Call it a case of opposites attracting: U.S.-based Perrigo specializes in cheap, store-brand generics, while Elan is an Irish biotech best know for its longstanding--and now dissolved--partnership with Biogen Idec on the multiple sclerosis drug Tysabri.

UPDATED: Perrigo targets Ireland tax perks in $8.6B Elan buyout

The chase for Elan appears to be over. Perrigo, a U.S. maker of over-the-counter and generic drugs, has emerged with a winning bid to acquire the Irish biotech outfit for $8.6 billion in cash and stock.

Perrigo nails down dermatology spot with $45M deal

Perrigo has further solidified its position in topical dermatology drugs, one of the areas in which prices have been escalating of late.

GOP or Dem? Some pharma donors don't hedge their bets

It's the endgame for 2012 election candidates--and for supporters that have shelled out cash to support their bids for votes. As usual, the pharma business is right there in the fray, with political action committees and employees donating hundreds of thousands, if not millions.

Bayer picks up Teva's animal health biz for $145M

In the second animal health deal announced in two days, generic drug giant Teva Pharmaceutical Industries says it will sell its animal products line to Bayer of Germany for $145 million so it can concentrate on human drugs.

Fast-growing generics maker Perrigo moves into pet care

The Michigan-based company, best known for its generics and OTC drugs, purchased Sergeant's Pet Care Products for $285 million.